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Introduction
Long-term central venous catheters (CVC) facilitate medical care for children with chronic illness, particularly those with cancer by providing easy venous access for blood tests, chemotherapy administration, parenteral nutrition, and other necessary intravenous medications. However, potential CVC complications include infection, mechanical dysfunction, thrombosis, and catheter occlusion, which can increase morbidity, interrupt treatment, and require catheter removal.
The most frequent CVC complication is occlusion, which occurs in 14-36% of children with cancer within 1-2 years of insertion. (1-6) Occlusion can be classified as partial (inability to aspirate blood, but ability to infuse through the catheter) or complete (inability to aspirate or infuse via the catheter). Although CVC obstruction is considered to be a clinically important issue according to 80% of pediatric oncology centers surveyed in the United Kingdom, differences in prevention, diagnosis, and treatment practices persist due to lack of evidence-based management guidelines. (7) This paper reviews thrombolytic treatment for catheter obstruction based on the current literature from Medline searches using the terms central venous catheter, central venous access device or central venous line associated with the terms obstruction, occlusion, treatment, or thrombolytic. Efficacy of thrombolytic therapy, CVC clearance rates, time to clearance, and the need for a second dose of thrombolytic were assessed and side effects of thrombolytic therapy reviewed. The emphasis of this review is management of long-term CVCs, so articles that focused on short-term CVCs or hemodialysis catheters were excluded. All original articles from the literature search that analyzed the treatment of long-term CVC occlusions with the thrombolytics discussed in this manuscript were included in the review.
Types of Catheter Obstruction
CVC obstruction can occur from mechanical causes, precipitation of a medication or parenteral nutrition, or as the result of a thrombotic process. Mechanical obstructions include problems such as a kink in the catheter or tubing, a tight suture, a catheter tip blocked by the vessel wall, a clamp left in the closed position on an external catheter or a needle dislodged or occluded when using implantable ports. An uncommon cause of mechanical obstruction that should be considered is the "pinch-off syndrome", a condition in which the catheter is compressed between the clavicle and the first rib.
While the pinch-off syndrome only occurs in about 1% of patients with a CVC, up to 40% of these cases develop fragmentation and subsequent embolization of the catheter tip into the central vascular system. (8, 9) Catheter obstructions can also be due to a non-thrombotic internal occlusion, such as precipitation of medications or parenteral nutrition constituents. Obstructions caused by precipitation of medications with a low pH and those due to calcium phosphate crystals can be treated with 0.1% hydrochloric acid (HCl 
Alteplase
Alteplase, also known as tissue plasminogen activator (t-PA), catalyzes the conversion of clot bound plasminogen to plasmin, which then activates the fibrinolysis cascade ( Figure 1 , Table 1 ). Already approved for treating acute myocardial infarctions, alteplase was studied to determine its efficacy as a means to clear catheter occlusions (Table 2 ). In one of the initial studies, alteplase was found to be superior to urokinase for the treatment of radiographically proven thrombotic occlusion of a CVC (59% of catheters cleared by urokinase vs. 89% by alteplase p=0.0013).
Considering the favorable results from this trial and the temporary removal of urokinase from the market, alteplase was investigated further as an alternative method for catheter clearance ( The high efficacy and low risk of alteplase for treating CVC occlusions in adults prompted studies in children. Several trials found that alteplase administered for 1-4
hours produced catheter clearance rates of 85-95% (Table 2) . (27-32) In a subset analysis of pediatric patients in the COOL trials and a multicenter trial using a dosing regimen and dwell times identical to those in the COOL trials, alteplase was confirmed to be safe and effective with overall catheter clearance rates of 83-87% and no adverse outcomes documented. (31,32)
New Medications for Thrombotic Catheter Occlusion
As illustrated by the preceding studies, alteplase produces a high rate of clearance of thrombotic catheter occlusions after relatively short dwell times of up to 2-4 hours. However, even this amount of time can cause delays in patient care and in critically ill patients can increase morbidity when venous access is needed urgently.
Moreover, catheters that do not regain patency require removal, exposing the patient to additional risks. New thrombolytics show promise of higher clearance rates and faster onset of action, which may further improve patient safety and the efficiency of care.
Reteplase, tenecteplase, recombinant urokinase, and alfimeprase have been evaluated for CVC occlusions and will be discussed below. Anistreplase is another type of thrombolytic medication, which so far has only been studied as treatment for cardiovascular disease in adults (Table 1) .
(33)
Reteplase
Reteplase is a variant of the tissue plasminogen activator that differs from alteplase in that it lacks several structural domains normally found in alteplase. These alterations may allow reteplase to bind less tightly to the clot and allow for increased diffusion, leading to an increased half-life and thrombus penetration ( Figure 1 and Table   1 ). (34) Studies analyzing the efficacy of reteplase indicate catheter clearance of 67-74% after 30-40 minutes with overall clearance rates ranging from 80-95% (Table 2 ).
(34-36) A maximum dose of 0.4 U was found to be safe with no increased risk of hemorrhage or treatment related side effects reported.
Tenecteplase
Tenecteplase is also a recombinant form of tissue plasminogen activator with a similar mechanism to alteplase. There are three amino acid changes that contribute to changes in the characteristics associated with this medication, such as increased specificity for plasmin, a half-life four times longer than alteplase, and an increased resistance to plasminogen activator inhibitor ( Figure 1 and Table 1 ). (37) Studies demonstrated resolution of the occlusion in 81-87% of patients and maintenance of patency in 80-81% of subjects after at least 7 days following administration ( Table 2 ).
(37, 38) This newer medication was found to be safe as well with only 6 serious adverse events noted in the subsequent 7 days, none of which were attributed to the therapy.
(37)
Recombinant Urokinase
Another option to manage CVC occlusions that has been explored in adults is the recombinant form of urokinase (r-UK), which directly cleaves plasminogen into plasmin to catalyze the fibrinolysis pathway ( Figure 1 and Table 1 ). Recent studies have demonstrated that r-UK, at a dose of 5000 IU/ml, was effective and safe, with 54-75% of occlusions cleared after up to two treatments, each lasting 30 minutes, and minimal adverse events in the subsequent 72 hours ( 
Alfimeprase
Alfimeprase is a truncated form of the metalloproteinase fibrolase, isolated from the Southern copperhead snake and reconstructed via recombinant DNA technology.
Alfimeprase has direct proteolytic activity against fibrin by binding to its Aα chain, which causes direct degradation of the thrombus, independent of the plasminogen activation system ( Figure 1 and 
Comparison of Thrombolytic Medications
Based on these studies, reteplase appears to be very effective in restoring patency to an occluded CVC. After only 30-40 min, catheter clearance rates for reteplase were 67-74% in comparison to the average rates of for alteplase (52%), recombinant urokinase (60%) and tenecteplase (52%) ( Investigators have also studied the use of thrombolytics, such as urokinase, to prevent CVC occlusions (Table 3 ). In two pediatric trials a statistically lower incidence of occlusive events was demonstrated in the urokinase group, 19%-23% versus 31-68%
in the control group. (1,54) Moreover, a prospective trial in adults reported that twicedaily heparin plus weekly urokinase was associated with a lower rate of CVC occlusions compared to heparin alone. (55) Additional studies were unable to corroborate these results (Table 3) . (56) Therefore, although some studies indicate urokinase prophylaxis may reduce CVC occlusions, additional studies are required to determine the optimal regimen and true efficacy. Moreover, considering that catheter clearance rates are 80-90% after only one or two doses of thrombolytic, the cost-effectiveness of prophylaxis requires evaluation before widespread implementation. Cost analysis should consider the cost of additional hospital or clinic time needed to treat an occluded catheter and account for any delay in treatment due to CVC dysfunction.
As a result of the association between CVC related obstruction and infection, many investigators have analyzed the effect of thrombolytic prophylaxis on the incidence of CVC infections as well ( Table 3 ). The two pediatric trials also demonstrated a reduced incidence of CVC infection in the treatment group. (1,54) A randomized trial comparing urokinase to placebo found a significantly lower incidence of major CVC-associated coagulase negative staphylococcus infections in the urokinase treatment group with a relative risk of 0.09 (95% CI, 0.01 to 0.5). (57) Two additional studies evaluated were unable to support these findings, although in these trials the urokinase was administered as a flush, not allowing the solution to dwell in the catheter lumen for any significant amount of time, which may have affected its efficacy (Table 3) .
(56, 58)
Although there are some conflicting data, it appears that urokinase prophylaxis decreases the rate of catheter-related infections and catheter-related thrombosis. (1,54) Therefore, the effect of prophylaxis on the complications associated with catheter occlusions, such as catheter infections, catheter-related thrombosis, and catheter removal, must also be analyzed in depth. While this practice may not have a substantial impact on thrombotic obstructions in CVCs, it may have a clinically important effect on the complications associated with these obstructions and should be studied further.
Conclusion
Catheter obstruction remains a common problem associated with CVC use.
Alteplase clears obstructed catheters safely and effectively, but may require a dwell time of up to 4 hours to achieve catheter clearance. Newer forms of thrombolytic therapy, such as reteplase, tenecteplase, and recombinant urokinase, safely and effectively treat CVC obstruction and require shorter dwell times than alteplase.
Alfimeprase, a new thrombolytic with a site of action separate from the plasminogen activation system, also rapidly clears thrombotic catheter occlusions, but it is unclear whether a treatment regimen with this medication would be superior to alteplase.
Further studies are required to directly compare alteplase with newer agents, with special attention to clearance rates at early time points (5, 15, and 30 minutes), in addition to overall clearance rates. Anticoagulation prophylaxis may reduce the incidence of catheter occlusions and infections in children, and possibly catheter-related thrombosis, but the cost-effectiveness and clinical impact of this practice has yet to be determined.
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With each dose, a maximum dwell time of 30 and 60 minutes were utilized for recombinant urokinase and reteplase respectively. Alteplase, alfimeprase, and tenecteplase used dwell times of a maximum of 120 minutes. 
